Halia Therapeutics Presented Data on Targeting the NLRP3 Inflammasome for the Treatment of Alzheimer's Disease
SALT LAKE CITY, March 30, 2022 /PRNewswire/ -- Halia Therapeutics, a biotechnology company that has used a structure-based drug design strategy to discover a series of small molecu…
